References
- Nissen N. I., Hansen S. W. High activity of daily-schedule mitoxantrone in newly diagnosed low-grade non-Hodgkin's lymphomas: a 5-year follow-up. Seminars in Oncology 1990; 17(suppl 10)10–13
- McLaughlin P., Hagemeister F. B., Swan F., et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. Journal of Clinical Oncology 1994; 12: 575–579
- McLaughlin P., Hagemeister F. B., Romaguera J. E., et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. Journal of Clinical Oncology 1996; 14: 1262–1268
- Zinzani P. L., Brendandi M., Tura S. FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. European Journal of Haematology 1995; 55: 262–266
- Zinzani P. L., Bendandi M., Magagnoli M., et al. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Annals of Oncology 1997; 8: 379–383
- Seymor J. F., Grigg A. P., Szer J., et al. Fludarabine and mitoxantrone: a highly effective and well-tolerated salvage therapy for low-grade lymphoproliferative disorders. Blood 1997; 90(suppl 1)343a, abstract #1530
- Emmanouilides C., Rosen P., Rasti S., et al. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial. Hematologic Oncology 1998; 16: 107–116
- Redman J. R., Cabanillas F., Velasquez W. S., et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. Journal of Clinical Oncology 1992; 10: 790–794
- Hochster H. S., Kim K., Green M. D., et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 1992; 10: 28–32
- Keating M. J., O'Brien S., Kantarjian H., et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–2884
- Silver R. T., Case D. C., Wheeler R. H., et al. Multi-center clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. Journal of Clinical Oncology 1991; 9: 754–761
- Gillis S., Dann E. J., Cass Y., et al. Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma-the Jerusalem experience. Leukemia and Lymphoma 1994; 15: 173–175
- Coltman C. A., Jr, McDaniel T. M., Balcerzak S. P., et al. Mitoxantrone hydrochloride (NSC-310739) in lymphoma: a Southwest Oncology Group study. Investigational New Drugs 1983; 1: 65–70
- Velasquez W., Lew D., Miller T., et al. SWOG 95–01: A phase II trial of a combination of fludarabine and mitoxantrone (FN) in untreated advanced low grade lymphoma. An effective, well tolerated therapy. Proceedings of the American Society of Clinical Oncology 1999; 18: 9a, abstract #27
- Ajani J. A., Welch S. R., Raber M. N., et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Investigations 1990; 8: 147–159
- Wright S., Huang P., Keating A. R., et al. High molecular weight DNA fragmentation induced by fludarabine and mitoxantrone in CLL cells. Blood 1994; 84(suppl 1)458a, abstract #1817
- Velasquez W. S., McLaughlin P., et al. ESHAP — An effective chemotherapy regimen in refractory and relapsing lymphoma — A 4-year follow-up study. Journal of Clinical Oncology 1994; 12: 1169–1176
- Rodriguez M. A., Cabanillas F. C., Velasquez W., et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. Journal of Clinical Oncology 1995; 13: 1734–1741